Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Sex differences in outcomes in multiple myeloma

“…In an analysis of 1 960 MM patients enrolled in a phase III clinical trial, sex was associated with overall survival (OS) on univariate analysis (median OS 44·8 months female vs 49·9 months male, P = 0·02) but was not significant in multivariate analysis. Similarly, an analysis of the Myeloma XI trial found no sex differences in progression‐free survival (PFS) or OS 3 …”

“…Similarly, an analysis of the Myeloma XI trial found no sex differences in progression-free survival (PFS) or OS. 3 In this report, we describe baseline characteristics and outcomes of patients with MM by sex using two large population-based datasets: the SEER dataset and the Multiple Myeloma Research Foundation (MMRF) CoMMpass dataset with clinical annotation.…”

“…Similarly, an analysis of the Myeloma XI trial found no sex differences in progression-free survival (PFS) or OS. 3 In this report, we describe baseline characteristics and outcomes of patients with MM by sex using two large population-based datasets: the SEER dataset and the Multiple Myeloma Research Foundation (MMRF) CoMMpass dataset with clinical annotation.We used MM data for the period 2000-2017 from SEER 18 that covers about 27Á8% of the United States population. We identified MM patients (n = 78,351) using the third edition of the International Classification of Diseases for Oncology (ICD-O-3) code 9732.…”

“…2 Because steroid-refractory aGVHD, esp. lower gastrointestinal (LGI) aGVHD, has a dismal prognosis, 3 early identification of patients unlikely to respond to front-line treatment is of critical importance and highlights a target population for novel therapeutics. Specifically, biomarkers of treatment refractoriness, if found before the onset of aGVHD, would potentially guide monitoring and preparation for high-risk disease in the following days to weeks.…”

Sozioökonomische Benachteiligung als Risikofaktor für Krebserkrankungen – „closing the care gap“

“…Aber aktuelle Forschungsbemühungen zeigten, dass die aufgeführten sozioökonomische Aspekte inkl. Einkommen, Beziehungs- und Sozialstatus sowie Notwendigkeit für sozialmedizinische Unterstützungsangebote systematischer erhoben werden müssen [ 28 , 30 , 31 ]. In eigenen Untersuchungen mit Patient*innen mit multiplem Myelom (MM) hatten 10 % der Studienteilnehmenden ein geringes Einkommen (definiert als < 1025 $/Monat) und 14 % waren ohne Partner*in/allein [ 32 ], was sich in einer prospektiven, randomisierten Sportinterventionsstudie mit Patient*innen mit MM (Manuskript in Vorbereitung) sogar als doppelt so hoch mit 19 % bzw.…”